These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33197421)

  • 1. Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.
    Xia H; Feng L; Lin L; Jiang Z; Chen J; Shi W; Ying S; Yu M; Ju L; Zhu L; Shi L; Zhang X; Lou J
    Environ Res; 2021 Feb; 193():110467. PubMed ID: 33197421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
    Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A
    Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
    Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
    Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.
    Jiang Z; Ying S; Shen W; He X; Chen J; Xia H; Yu M; Xiao Y; Feng L; Zhu L; Ju L; Guo X; Zhang Y; Shen JW; Tong Y; Zhang X; Lou J
    Dis Markers; 2017; 2017():1725354. PubMed ID: 29200597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin's Lymphoma.
    Yu R; Cheng L; Yang S; Liu Y; Zhu Z
    Front Oncol; 2022; 12():848286. PubMed ID: 35371990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
    Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
    Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
    Pei D; Li Y; Liu X; Yan S; Guo X; Xu X; Guo X
    Oncotarget; 2017 Feb; 8(8):13030-13038. PubMed ID: 28103581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
    Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
    N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid profiling in malignant mesothelioma reveals promising signatures for diagnosis and prognosis: A plasma-based LC-MS lipidomics study.
    Chen Z; Song S; Yang C; Dai Z; Gao Y; Li N; Zhu J; Mao W; Liu J
    Clin Chim Acta; 2022 Jan; 524():34-42. PubMed ID: 34843704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.
    Ying S; Jiang Z; He X; Yu M; Chen R; Chen J; Ru G; Chen Y; Chen W; Zhu L; Li T; Zhang Y; Guo X; Yin X; Zhang X; Lou J
    Dis Markers; 2017; 2017():5756102. PubMed ID: 28348451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
    Kaya H; Demir M; Taylan M; Sezgi C; Tanrikulu AC; Yilmaz S; Bayram M; Kaplan I; Senyigit A
    Asian Pac J Cancer Prev; 2015; 16(4):1403-7. PubMed ID: 25743806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
    Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.